作为VEGFR-2抑制剂的1,3,4-提亚衍生物及其癌症治疗的分子洞察力
Pragya Gawande1, Balaji Wamanrao Matore1, Anjali Murmu1
1Laboratory of Drug Discovery and Ecotoxicology, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.
Chemistry & biodiversity
|August 26, 2025
概括
作为针对血管内皮生长因子受体-2 (VEGFR-2) 的新型抑制剂,1,3,4- 亚醇衍生物在癌症治疗中具有前景. 与现有治疗方法相比,这些化合物具有提高选择性和降低毒性的潜力.
科学领域:
- 癌症学
- 医学化学
- 分子生物学
背景情况:
- 血管内皮生长因子受体-2 (VEGFR-2) 对瘤生长,血管生成和转移至关重要.
- 目前的VEGFR-2抑制剂面临挑战,包括耐药性,毒性和缺乏选择性.
- 1,3,4-thiadiazole (TDA) 支架为开发新的抗癌药物提供了一个有前途的结构.
研究的目的:
- 审查VEGFR-2在癌症中的作用.
- 探索1,3,4-TDA衍生物的化学和VEGFR-2抑制机制.
- 分析结构-活性关系 (SAR) 并指导新型抑制剂的设计.
主要方法:
- 在过去十年中发表的基于1,3,4-TDA的VEGFR-2抑制剂的系统文献综述.
- 对151种TDA衍生物的分析,评估化学空间,SAR,选择性,毒性和结合相互作用.
- 检查TDA支架的特定化学特征,这些特征有助于VEGFR-2结合.
主要成果:
- 1,3,4-TDA衍生物具有显著的VEGFR-2抑制潜力.
- 涉及TDA支架的基因和硫原子的关键分子相互作用对VEGFR-2结合至关重要.
- 分析发现了影响抑制剂有效性和选择性的特定替代模式和SAR趋势.
结论:
- 1,3,4-TDA衍生物为开发下一代VEGFR-2抑制剂提供了宝贵的支架.
- 这些化合物为设计更有选择性,更少毒性的抗癌疗法提供了战略优势.
- 对基于TDA的抑制剂的进一步研究可以带来更好的抗癌药物候选药物.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


